hotspot -WSS

hotspot

author：explore 2025-09-06 03:17:22 - browse：54

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： STAT Virtual Event: ASCO Recap, Live!

WSS

NIH tests clinical research in primary care with $30 million program

U.S. death rates show how politics are affecting public health

Congress: Prevent baby formula shortages by passing a new bill

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

'Essentially witchcraft:' A former naturopath takes on the field

Achieving telehealth equity for people with hearing loss

leisure time

hotspot

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

The world needs the new pandemic treaty

After affirmative action ruling, medical educators look to 'holistic review'

Louisiana bill approved classifying abortion pills as controlled substances

Medical leaders decry Supreme Court decision on affirmative action

STAT Virtual Event: ASCO Recap, Live!

23andMe had bad news about my health. I wish a person had delivered it

Protect nursing home residents from future pandemics

Duchenne breakthrough therapy leaves behind pioneering families

NIH tests clinical research in primary care with $30 million program

focus

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Ozempic cut risk of death in diabetes patients with chronic kidney disease

ALS patient reclaims some autonomy thanks to wearable 'robot'

The world needs the new pandemic treaty

The world needs the new pandemic treaty

The Bio Revolution is changing business and society

explore

hotspot

hotspot

focus